Active compounds-based discoveries about the differentiation and apoptosis of leukemic cells  

作　　者：CHEN GuoQiang ZHANG Jing ZHAO Qian 

机构地区：[1]Department of Pathophysiology and E-Institute of Chemical Biology of Shanghai Universities, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine (SJTU-SM) Shanghai 200025, China [2]Institute of Health Science, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences & SJTU-SM, Shanghai 200025. China

出　　处：《Chinese Science Bulletin》2009年第22期4094-4101,共8页

基　　金：Supported in part by the National High Technology Research and Development Program of China (Grant No. 2008AA02Z301);National Key Basic Research and Development Program of China (Grant Nos. 2009CB918400 and 2002CB512800);National Natural Science Foundation of China (Grant Nos. 90813034, 30500215, 30600216, and 30800452);Knowledge Innovation Project of the Chinese Academy of Sciences (Grant No. KSCX2-YW-R-097);the Shanghai Committee of Science and Technology, China (Grant Nos. 08JC1413700 and 08JC1413500)

摘　　要：Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic malignancies which are characterized by the blockage of hematopoietic cell differentiation with uncontrolled proliferation and/or impaired apoptosis. Over the past 20 years, there has been tremendous progress in the biological, molecular, and cytogenetic aspects of the disease, accompanied by significant advancements in the treatment of AML patients. For example, all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) have been used clinically for effective treatments of patients with acute promyelocytic leukemia (APL, a unique subtype of AML) through differentiation and/or apoptosis induction. More intriguingly, these active compounds-based chemical biological studies greatly accelerated our understanding on leukemogenesis and targeted therapy of AML patients. Based on some recent findings mainly from our group, this review attempts to summarize the related advances from Chinese researchers.Acute myeloid leukemia （AML） is a heterogeneous group of hematopoietic malignancies which are characterized by the blockage of hematopoietic cell differentiation with uncontrolled proliferation and/or impaired apoptosis. Over the past 20 years, there has been tremendous progress in the biological, molecular, and cytogenetic aspects of the disease, accompanied by significant advancements in the treatment of AML patients. For example, all-trans retinoic acid （ATRA） and arsenic trioxide （As2O3） have been used clinically for effective treatments of patients with acute promyelocytic leukemia （APL, a unique subtype of AML） through differentiation and/or apoptosis induction. More intriguingly, these active compounds-based chemical biological studies greatly accelerated our understanding on leukemogenesis and targeted therapy of AML patients. Based on some recent findings mainly from our group, this review attempts to summarize the related advances from Chinese researchers.

关 键 词：急性早幼粒细胞白血病 活性化合物 细胞凋亡 细胞分化 化学生物学 全反式维甲酸 靶向治疗 细胞遗传学 

分 类 号：Q255[生物学—细胞生物学] TQ466.1[化学工程—制药化工]